Table 2.
Concordance in risk stratification between the BCT score and Oncotype DX RS according to nodal status and age.
|
All (n = 771) |
Lymph node-negative (n = 619) |
Lymph node-positive (n = 152) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Oncotype DX RS (TAILORx cut-off) |
Oncotype DX RS (TAILORx cut-off) |
Oncotype DX RS (TAILORx cut-off) |
||||||||
| n (%) | Non-high risk (0–25) | High risk (≥26) | Total | Non-high risk (0–25) | High risk (≥26) | Total | Non-high risk (0–25) | High risk (≥26) | Total | |
| BCT score | Low risk (<4) | 480 (62.3%) |
47 (6.1%) |
527 (68.4%) |
414 (66.9%) |
43 (6.9%) |
457 (73.8%) |
66 (43.4%) |
4 (2.6%) |
70 (46.1%) |
| High risk (≥4) | 170 (22.0%) |
74 (9.6%) |
244 (31.6%) |
102 (16.5%) |
60 (9.7%) |
162 (26.2%) |
68 (44.7%) |
14 (9.2%) |
82 (53.9%) |
|
| Total | 650 (84.3%) |
121 (15.7%) |
771 (100.0%) |
516 (83.4%) |
103 (16.6%) |
619 (100.0%) |
134 (88.2%) |
18 (11.8%) |
152 (100.0%) |
|
| ≤50 YEARS | ||||||||||
|
Oncotype DX RS (TAILORx cut-off) |
Oncotype DX RS (TAILORx cut-off) |
Oncotype DX RS (TAILORx cut-off) |
||||||||
| n (%) |
Non-chemobenefit (0–15) |
Chemobenefit (≥16) |
Total |
Non-chemobenefit (0–15) |
Chemobenefit (≥16) |
Total |
Non-chemobenefit (0–15) |
Chemobenefit (≥16) |
Total | |
| BCT score | Low risk (<4) | 168 (32.7%) |
182 (35.4%) |
350 (68.1%) |
143 (34.9%) |
156 (38.0%) |
299 (72.9%) |
25 (24.0%) |
26 (25.0%) |
51 (49.0%) |
| High risk (≥4) | 60 (11.7%) |
104 (20.2%) |
164 (31.9%) |
36 (8.8%) |
75 (18.3%) |
111 (27.1%) |
24 (23.1%) |
29 (27.9%) |
53 (51.0%) |
|
| Total | 228 (44.4%) |
286 (55.6%) |
514 (100.0%) |
179 (43.7%) |
231 (56.3%) |
410 (100.0%) |
49 (47.1%) |
55 (52.9%) |
104 (100.0%) |
|
| >50 YEARS | ||||||||||
|
Oncotype DX RS (TAILORx cut-off) |
Oncotype DX RS (TAILORx cut-off) |
Oncotype DX RS (TAILORx cut-off) |
||||||||
| n (%) |
Non-chemobenefit (0–25) |
Chemobenefit (≥26) |
Total |
Non-chemobenefit (0–25) |
Chemobenefit (≥26) |
Total |
Non-chemobenefit (0–25) |
Chemobenefit (≥26) |
Total | |
| BCT score | Low risk (<4) | 159 (61.9%) |
18 (7.0%) |
177 (68.9%) |
140 (67.0%) |
18 (8.6%) |
158 (75.6%) |
19 (39.6%) |
0 (0.0%) |
19 (39.6%) |
| High risk (≥4) | 52 (20.2%) |
28 (10.9%) |
80 (31.1%) |
29 (13.9%) |
22 (10.5%) |
51 (24.4%) |
23 (47.9%) |
6 (12.5%) |
29 (60.4%) |
|
| Total | 211 (82.1%) |
46 (17.9%) |
257 (100.0%) |
169 (80.9%) |
40 (19.1%) |
209 (100.0%) |
42 (87.5%) |
6 (12.5%) |
48 (100.0%) |
|
BCT, Breast Cancer Test; RS, recurrence score; TAILORx, Trial Assigning Individualized Options for Treatment.